rivastigmine / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
rivastigmine / Generic mfg.
2008-008896-32: Memory, Ageing, and the Cholinergic System a combined fMRI and PET study

Ongoing
2
40
Europe
N-[C-11]-Methylpiperidin-4-yl-acetate, C11-MP4A, Capsule, Solution for injection, Exelon
University of Cologne
Patients with mild cognitive impairment (MCI) (50-80 years), who are at greater risk of developing alzheimer's dementia will be recruited in the present study and will be compared to an age-matched group of healthy subjects (50-80 years).
 
 
2004-000507-17: Effectiveness of rivastigmine treatment in post-stroke patients with right brain damage and unilateral spatial neglect

Ongoing
2
20
Europe
Rivastigmine, NA,
FONDAZIONE SANTA LUCIA
Improvement of unilateral spatial neglect and functional status in right brain damaged patients
 
 
RIVA-AM, NCT06382649: Rivastigmine for Antimuscarinic Delirium

Not yet recruiting
2
42
US
Rivastigmine, Placebo
Washington University School of Medicine, American Academy of Clinical Toxicology
Anticholinergic Toxicity
07/26
07/26
RIVA-AP, NCT06399679: Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium

Not yet recruiting
2
42
US
Rivastigmine, Placebo
Washington University School of Medicine, American Academy of Clinical Toxicology
Anticholinergic Toxicity
07/26
07/26

Download Options